The KCNQ/KV7 potassium channel opener Retigabine as add-on therapy for partial epilepsy. Pharmacological and clinical data

被引：0
|
作者：
Orhan, Goekce [1 ]
Wuttke, Thomas V. [2 ,3 ,4 ,5 ]
Nies, Anne T. [6 ]
Schwab, Matthias [6 ,7 ]
Lerche, Holger [1 ]
机构：
[1] Univ Tubingen, Hertie Inst Klin Hirnforsch, Abt Neurol Schwerpunkt Epileptol, D-72076 Tubingen, Germany
[2] Harvard Univ, Sch Med, Dept Neurosurg, MGH HMS Ctr Nervous Syst Repair, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Dept Neurol, MGH HMS Ctr Nervous Syst Repair, Boston, MA 02114 USA
[4] Harvard Univ, Program Neurosci, Sch Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Nayef Al Rodhan Labs, Boston, MA 02114 USA
[6] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[7] Univ Klinikum Tubingen, Klin Pharmakol Abt, Inst Expt & Klin Pharmakol & Toxikol, D-72076 Tubingen, Germany
来源：
PSYCHOPHARMAKOTHERAPIE | 2011年 / 18卷 / 04期
关键词：
Epilepsy; potassium channel; pharmacotherapy; antiepileptic drug; retigabine; ANTICONVULSANT RETIGABINE; PHARMACOKINETIC INTERACTION; DIFFERENT PATTERNS; N-GLUCURONIDATION; HUMAN LIVER; D-23129; ACTIVATION; MODEL; CURRENTS; BINDING;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The KCNQ/K(V)7 potassium channel opener Retigabine as add-on therapy for partial epilepsy. Pharmacological and clinical data This review summarizes the pharmacological, preclinical and clinical data on the new anticonvulsant compound retigabine (RGB) and discusses the impact of this drug for patients with refractory partial epilepsy. Retigabine increases the activity of voltage-gated KCNQ/K(V)7 channels and thus exhibits a novel mechanism of action as compared to available anticonvulsive drugs. Retigabine has been investigated in three multicenter, randomized, double-blind and placebo-controlled clinical phase 11 and III trials in adults with >= 4 partialonset seizures per month and showed efficacy in pharmacoresistant epilepsy. In march 2011, Retigabine received approval in Europe as Trobalt (R).
引用
收藏
页码：148 / +
页数：8
相关论文
共 43 条
  • [21] SUPPRESSION OF KV7/KCNQ POTASSIUM CHANNEL ENHANCES NEURONAL DIFFERENTIATION OF PC12 CELLS
    Zhou, Najing
    Huang, Sha
    Li, Li
    Huang, Dongyang
    Yan, Yunli
    Du, Xiaona
    Zhang, Hailin
    NEUROSCIENCE, 2016, 333 : 356 - 367
  • [22] Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy
    Zhang, Fan
    Liu, Yani
    Tang, Feng
    Liang, Bo
    Chen, Huanming
    Zhang, Hailin
    Wang, KeWei
    FASEB JOURNAL, 2019, 33 (08): : 9154 - 9166
  • [23] Neuroprotective Effects, Mechanisms of Action and Therapeutic Potential of the Kv7/KCNQ Channel Opener QO-83 in Ischemic Stroke
    Zhang, Huiran
    Tian, Yanfei
    Zhang, Yan
    Wang, Yan
    Qi, Jinlong
    Wang, Xiangyu
    Yuan, Yi
    Chen, Rong
    Zhao, Yupeng
    Liu, Chang
    Zhou, Najing
    Liu, Lanxin
    Hao, Han
    Du, Xiaona
    Zhang, Hailin
    TRANSLATIONAL STROKE RESEARCH, 2025,
  • [24] Kv7 potassium channel openers: new indications for the therapy of movement disorders?
    Sander, S. E.
    Richter, A.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2009, 32 : 230 - 230
  • [25] Electrophysiological and Pharmacological Characterization of a Novel and Potent Neuronal Kv7 Opener SCR2682 for Anti-Epilepsy
    Liu, Yani
    Zhang, Fan
    Liang, Bo
    Chen, Huangming
    Zhang, Hailin
    Wang, Kewei
    BIOPHYSICAL JOURNAL, 2019, 116 (03) : 544A - 544A
  • [26] Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain
    Wang, Jing
    Liu, Yani
    Hu, Fang
    Yang, Jiuyong
    Guo, Xiaoyu
    Hou, Xingming
    Ju, Chuanxia
    Wang, KeWei
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2021, 377 (01): : 20 - 28
  • [27] Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: The European experience
    BenMenachem, E
    EPILEPSIA, 1997, 38 : S28 - S30
  • [28] Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity
    Musella, Simona
    Carotenuto, Lidia
    Iraci, Nunzio
    Baroli, Giulia
    Ciaglia, Tania
    Nappi, Piera
    Basilicata, Manuela Giovanna
    Salviati, Emanuela
    Barrese, Vincenzo
    Vestuto, Vincenzo
    Pignataro, Giuseppe
    Pepe, Giacomo
    Sommella, Eduardo
    Di Sarno, Veronica
    Manfra, Michele
    Campiglia, Pietro
    Gomez-Monterrey, Isabel
    Bertamino, Alessia
    Taglialatela, Maurizio
    Ostacolo, Carmine
    Miceli, Francesco
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 11340 - 11364
  • [29] Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial epilepsy.
    Hsiang-Yu, Y
    Der-Jen, Y
    Chun-Hing, Y
    Ming-Shung, S
    EPILEPSIA, 1999, 40 : 97 - 97
  • [30] The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels
    Brickel, Neil
    Gandhi, Paul
    VanLandingham, Kevan
    Hammond, Janet
    DeRossett, Sarah
    EPILEPSIA, 2012, 53 (04) : 606 - 612
12345